Texcell North America starts work on new Maryland facility

URLhttps://www.biopharma-reporter.com/Article/2022/01
SourceBio Pharma Reporter
Date Published01/22/2022
Author NameRachel Arthur
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Texcell North America
Parent companyTexcell Group
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2022
Year reshoring implemented or to be implemented:2023
Domestically, the work will be done:In-house
Country(ies) from which reshored:France
City reshored to:Frederick
State(s) reshored to:MD
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredviral clearance, safety testing, CRO
What domestic positive factors made reshoring more attractive?Infrastructure, Proximity to customers/market
Find Reshoring Articles